Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.

The American journal of surgical pathology - 1 Aug 2010

Capper David, Sahm Felix, Hartmann Christian, Meyermann Richard, von Deimling Andreas, Schittenhelm Jens

Abstract excerpt

Differentiation of gliomas and reactive gliosis may be challenging both at primary tumor occurrence and at posttherapy biopsy. The most frequent IDH1 mutation found in the majority of WHO grade II and III gliomas can be visualized with an antibody specifically detecting mutant IDH1 protein. In this study, mIDH1R132H immunoreactivity in 120 reactive gliosis specimens of various etiologies is compared with Wilms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Specificity
Share to Biopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Gliosis

Share to Isocitrate Dehydrogenase

Share to Neuroglia

Share to WT1 Proteins

Source

Identifiers

PMID: 20661018
DOI: 10.1097/PAS.0b013e3181e7740d

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.PMID 20661018Read ↗

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Semantic proximity Read ↗

The definition of primary and secondary glioblastoma.Semantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.Semantic proximity Read ↗

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.Semantic proximity Read ↗

Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.Semantic proximity Read ↗

Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.Semantic proximity Read ↗

IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.Semantic proximity Read ↗

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.Semantic proximity Read ↗

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.Semantic proximity Read ↗

IDH-wildtype secondary glioblastoma arising in IDH-mutant diffuse astrocytoma: a case report.Semantic proximity Read ↗

Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.